Price Alert

Axsome Therapeutics Inc. (AXSM)

NASDAQ: AXSM · Real-Time Price · USD

109.65

0.90 (0.83%)

At close: Aug 15, 2025, 2:32 PM

Axsome Therapeutics Statistics

Share Statistics

Axsome Therapeutics has 49.9M shares outstanding. The number of shares has increased by 2.58% in one year.

Shares Outstanding	49.9M
Shares Change (YoY)	2.58%
Shares Change (QoQ)	0.97%
Owned by Institutions (%)	75.71%
Shares Floating	40.99M
Failed to Deliver (FTD) Shares	13,830
FTD / Avg. Volume	2.04%

Short Selling Information

The latest short interest is 3.63M, so 7.44% of the outstanding shares have been sold short.

Short Interest	3.63M
Short % of Shares Out	7.44%
Short % of Float	8.9%
Short Ratio (days to cover)	6.04

Valuation Ratios

The PE ratio is -14.11 and the forward PE ratio is 90.28. Axsome Therapeutics's PEG ratio is -1.03.

PE Ratio	-14.11
Forward PE	90.28
PS Ratio	10.51
Forward PS	5.3
PB Ratio	71.1
P/FCF Ratio	-31.5
PEG Ratio	-1.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Axsome Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.11, with a Debt / Equity ratio of 3.38.

Current Ratio	2.11
Quick Ratio	2.04
Debt / Equity	3.38
Debt / EBITDA	-0.71
Debt / FCF	-1.5
Interest Coverage	-42.71

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$541.7K
Profits Per Employee	$-403.39K
Employee Count	712
Asset Turnover	0.68
Inventory Turnover	2.12

Taxes

Income Tax	85K
Effective Tax Rate	-0.03%

Stock Price Statistics

The stock price has increased by 22.41% in the last 52 weeks. The beta is 0.51, so Axsome Therapeutics's price volatility has been higher than the market average.

Beta	0.51
52-Week Price Change	22.41%
50-Day Moving Average	105.89
200-Day Moving Average	105.12
Relative Strength Index (RSI)	49.54
Average Volume (20 Days)	677,091

Income Statement

In the last 12 months, Axsome Therapeutics had revenue of 385.69M and earned -287.22M in profits. Earnings per share was -5.99.

Revenue	385.69M
Gross Profit	352.39M
Operating Income	-280.56M
Net Income	-287.22M
EBITDA	-272.6M
EBIT	-280.56M
Earnings Per Share (EPS)	-5.99

Full Income Statement

Balance Sheet

The company has 315.35M in cash and 192.96M in debt, giving a net cash position of 122.4M.

Cash & Cash Equivalents	315.35M
Total Debt	192.96M
Net Cash	122.4M
Retained Earnings	-1.12B
Total Assets	639.78M
Working Capital	194.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -128.41M and capital expenditures -270K, giving a free cash flow of -128.68M.

Operating Cash Flow	-128.41M
Capital Expenditures	-270K
Free Cash Flow	-128.68M
FCF Per Share	-2.69

Full Cash Flow Statement

Margins

Gross margin is 91.37%, with operating and profit margins of -72.74% and -74.47%.

Gross Margin	91.37%
Operating Margin	-72.74%
Pretax Margin	-74.45%
Profit Margin	-74.47%
EBITDA Margin	-70.68%
EBIT Margin	-72.74%
FCF Margin	-33.36%

Dividends & Yields

AXSM does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AXSM is $178, which is 71.2% higher than the current price. The consensus rating is "Buy".

Price Target	$178
Price Target Difference	71.2%
Analyst Consensus	Buy
Analyst Count	14

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	2.78
Piotroski F-Score	4